Question Everything. See who's reporting it.

Dr Reddy's halts semaglutide supply over quality concerns

Source: Business Standard

The story in brief

Dr Reddy's Laboratories faced supply issues with its semaglutide injection, Obeda, after certain batches were found out of specification. The company is investigating the cause and ensuring product quality, though it did not specify when the issues would resolve. Semaglutide is a key ingredient in Novo Nordisk's diabetes and obesity drugs, and over half a dozen Indian firms have launched cheaper alternatives.

3 outletsSee what the other 2 outlets said

NEWXFree on Android and iPhone. Open in NEWX